San Diego, January 27, 2026
Revelation Biosciences Inc. has announced a 1-for-4 reverse stock split effective January 28, 2026, aimed at boosting its share price to comply with Nasdaq’s listing requirements. The company’s common stock will continue to be traded under the symbol ‘REVB’. Shareholders’ fractional shares will be rounded up, ensuring they maintain their ownership without needing to take action for post-split shares. The split comes amid ongoing advancements in the company’s healthcare initiatives and recent capital raising efforts.
San Diego, CA – Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a 1-for-4 reverse stock split, effective January 28, 2026. This strategic decision aims to bolster the market price per share to satisfy the minimum bid continued listing requirement of The Nasdaq Capital Market. Following the split, the company’s common stock will continue to trade under the existing symbol “REVB,” offering investors a fresh opportunity to engage with the company’s evolving market position. A new CUSIP number, 76135L804, will be assigned to the common stock after the reverse stock split.
Details of the Reverse Stock Split
- Effective Date: January 28, 2026
- Split Ratio: 1-for-4
- Trading Symbol Post-Split: REVB
- CUSIP Number Post-Split: 76135L804
This reverse stock split is intended to enhance the market price of the company’s common stock, a crucial step for regaining compliance with Nasdaq’s listing standards. The adjustments will be proportionately applied to the conversion and exercise prices of warrants, restricted stock unit awards, stock options, and the shares issued under the company’s equity incentive plans, ensuring a seamless transition for current stakeholders.
Impact on Shareholders
Shareholders receiving fractional shares due to the split will see their holdings rounded up to the nearest whole share, preserving their ownership interest in the company. Importantly, this reverse stock split will not alter any shareholder’s relative stake, nor will it change the par value of the common stock or modify the rights or preferences associated with it. Individuals holding shares in book-entry form will not need to take any action to receive their post-split shares, simplifying the process for both registered stockholders and those with brokered accounts.
Background on Revelation Biosciences Inc.
Revelation Biosciences Inc. is a clinical-stage life sciences company focused on leveraging its proprietary formulation, Gemini, to address inflammation-related health issues. With multiple ongoing programs exploring Gemini’s potential applications for acute kidney injury, chronic kidney disease, and post-surgical infection prevention, the company is at the forefront of innovative healthcare solutions designed to enhance patient outcomes and reduce systemic health challenges.
Recent Developments
- January 23, 2026: The company announced the exercise of certain outstanding warrants to purchase up to 13,065,000 shares of common stock at $0.86 per share, culminating in gross proceeds of $11 million. Closing of this offering is expected around January 26, 2026, pending customary closing conditions.
- January 21, 2026: Revelation reached a pivotal agreement with the U.S. Food and Drug Administration (FDA) regarding an approval pathway for Gemini as a treatment for acute kidney injury, indicating that a well-controlled adaptive Phase 2/3 clinical study with approximately 300 patients could support a new drug application.
- January 14, 2026: The initiation of Good Manufacturing Practice (GMP) manufacturing for Gemini and placebo has been announced to ensure a reliable supply of clinical drugs for upcoming studies.
Stock Performance
As of January 27, 2026, Revelation Biosciences Inc. (REVB) is trading at $0.5501 per share, with an approximate market capitalization of $2.41 million. Over the past week, the stock has seen a decline of 31.94%, alongside a significant decrease of 94.52% over the last year. Furthermore, the company currently reports a negative earnings per share (EPS) ratio of -$5.32, underlining the challenges it faces as it seeks to stabilize and advance its market position.
Forward-Looking Statements
This announcement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties, which may cause actual results to differ significantly from projections. Investors are encouraged to consider these risks and not to place undue reliance on these forward-looking statements.
Contact Information
For more information, please visit www.RevBiosciences.com.
Frequently Asked Questions (FAQ)
What is the reverse stock split ratio for Revelation Biosciences (REVB)?
Revelation announced a 1-for-4 reverse stock split effective January 28, 2026.
When will REVB trade on a post-split basis and under what symbol?
Shares will trade on a post-split basis at the start of trading on January 28, 2026 under the existing symbol REVB.
Will my warrants, stock options, or RSUs be affected by the REVB reverse split?
Yes; the company will make proportionate adjustments to conversion and exercise prices and to the number of shares issuable.
What happens if I would receive a fractional share after the REVB reverse split?
Holders entitled to fractional shares will be rounded up to the nearest whole share.
Will the REVB CUSIP or transfer agent change after the reverse split?
Yes; the post-split CUSIP will be 76135L804 and Continental Stock Transfer & Trust Co. will maintain book-entry records.
Do shareholders need to take any action to receive post-split REVB shares?
Registered stockholders in book-entry form need not act; brokered accounts will be adjusted automatically subject to each broker’s processes.
Key Features of the Announcement
| Feature | Details |
|---|---|
| Effective Date | January 28, 2026 |
| Split Ratio | 1-for-4 |
| Trading Symbol Post-Split | REVB |
| CUSIP Number Post-Split | 76135L804 |
| Current Stock Price | $0.5501 per share |
| Market Capitalization | Approximately $2.41 million |
| Recent Proceeds from Warrants | $11 million |
Deeper Dive: News & Info About This Topic
HERE Resources
Point Loma Nazarene University Hosts Community Day with Free Basketball Games
Revelation Biosciences Raises $11 Million Through Warrant Exercise
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
